Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + gemcitabine + ifosfamide + etoposide + L-asparaginase + dexamethasone + aprepitant
- Development stage
- Unknown
- Lead developer
- The University of Hong Kong
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
SIMPLE is a combination chemotherapy regimen developed by The University of Hong Kong for the treatment of natural killer (NK) cell malignancies, specifically extranodal NK/T-cell lymphoma and aggressive NK leukaemia. The regimen is a modification of the earlier PIGLETS protocol, renamed to avoid religious insensitivity and updated to include the neurokinin-1 receptor antagonist aprepitant to better manage chemotherapy-induced nausea and vomiting. SIMPLE consists of cisplatin, gemcitabine, ifosfamide, etoposide, L-asparaginase, and dexamethasone. It is currently being evaluated in a Phase 3 non-inferiority trial against the SMILE regimen, aiming to provide a comparable therapeutic effect with a lower risk of nephrotoxicity.
- Other names
- SIMPLE chemotherapyPIGLETS chemotherapySIMPLE regimenPIGLETS regimen
02
Targets
DNA polymerase familyTOP2A (DNA topoisomerase II)RNR (Ribonucleotide reductase)GR (Glucocorticoid receptor)DNATACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on cisplatin + gemcitabine + ifosfamide + etoposide + L-asparaginase + dexamethasone + aprepitant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + gemcitabine + ifosfamide + etoposide + L-asparaginase + dexamethasone + aprepitant.